Treatment Satisfaction of Patients with Psoriasis

Abstract

Treatment satisfaction of patients with psoriasis largely depends on the treatment modality, but evidence on preferences for specific medications is scarce. Here we assessed treatment satisfaction of 200 participants with moderate-to-severe psoriasis from a German University hospital with a 5-point scale and the Treatment Satisfaction Questionnaire for Medication (TSQM) and determined sociodemographic and disease-related influence factors. Participants obtaining biologicals and traditional systemic medications were significantly more satisfied than those receiving phototherapy or topical agents (TSQM = 323.3, 288.0, 260.6 or 266.8; p < 0.001). The highest TSQM score was calculated for ustekinumab (350.1), followed by acitretin (338.1), adalimumab (323.0), fumaric acid esters (304.7), infliximab (300.2), etanercept (298.8), and methotrexate (272.3; p < 0.001). High disease-related quality of life impairment (β = -0.437, p < 0.001) and psoriatic arthritis (β = -0.185, p = 0.005) were associated with decreased satisfaction. Optimising satisfaction is essential to improve adherence and outcome. We show high preferences for biologicals, particularly ustekinumab, but also good satisfaction with certain traditional medications.

Patient Adherence to Biologic Agents in Psoriasis

“…Our patients seemed to regain good life quality, as documented by the low DLQI values throughout the treatment. Previous studies documented generally high satisfaction with biologic treatment in psoriasis [25], which could be confirmed in our cohort by the results of the MARS questionnaire sampling patients' beliefs and attitudes. In spite of the fact that low levels of nonadherence precluded conclusive analyses of correlation between psychologic factors and drug adherence, we observed that the patients with an MPR <0.8 had a lower TS on the MARS.…”

“…Messy and time-consuming topical treatments are less favored by patients compared to injectable agents or oral treatments [20,22,25]. Surprisingly, injectable drugs seem to be preferred over orally administered medicine [22], which helps in understanding the high adherence to biologics in our study.…”

“…4). Other authors have also reported lower adherence to etanercept than to ustekinumab or adalimumab [19,25]. …”

Circular RNA Expression Profile and Analysis of Their Potential Function in Psoriasis

“…Many factors are involved, such as immunity, inflammation, cell proliferation, and apoptosis, and neurotransmitter and intracellular signal transduction pathways [5]. The immune factor-mediated inflammatory reaction can promote abnormal proliferation of KCs, ultimately leading to psoriasis; however, a satisfactory therapeutic effect on psoriasis can be achieved by inhibiting inflammation [6].…”

Patients engagemnet in clinical trial input

“…I parametri principali per determinare la soddisfazione dei pazienti per il trattamento sono l'efficacia e la via di somministrazione [19]. Uno studio recentemente condotto in Germania ha confermato che nella psoriasi moderata-severa i farmaci biotecnologici vengono preferiti ai farmaci sistemici tradizionali per l'elevata efficacia, il favorevole profilo rischio-beneficio e la comoda modalità di impiego [24]. Evidenze derivate da studi clinici interventistici e studi osservazionali hanno mostrato che il raggiungimento della condizione di clear skin è significativo sia in termini di definizione di gravità della malattia sia di QoL secondo la prospettiva del paziente.…”